Floatz logo

Tsc-201-B0702

HPV-Related Anal Squamous Cell Carcinoma

TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the HPV-Related Anal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Columbia University
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Carboplatin
Fudan University
Phase 3BB
Atezolizumab
Oncolytics Biotech
Phase 2B

View all 39 →

Same molecule, other indications

Tsc-201-B0702 is also rated in:

anogenital human papillomavirus infectionDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →